Cargando…

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy

Although immune checkpoint inhibitors targeting T-cell immunoregulatory proteins have revolutionized cancer treatment, they are effective only in a limited number of patients, and new strategies are needed to enhance tumor responses to immunotherapies. Deletion of protein tyrosine phosphatase non-re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Zhouting, Tang, Rachel, Huff, Sarah, Kummetha, Indrasena Reddy, Wang, Lingling, Li, Na, Rana, Tariq M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035454/ https://www.ncbi.nlm.nih.gov/pubmed/36968224 http://dx.doi.org/10.1158/2767-9764.CRC-21-0186

Ejemplares similares

HIV-1 Escape from Small-Molecule Antagonism of Vif
por: Sharkey, Mark, et al.
Publicado: (2019)

Rational Design and Optimization of m(6)A-RNA Demethylase FTO Inhibitors as Anticancer Agents
por: Huff, Sarah, et al.
Publicado: (2022)

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
por: Huff, Sarah, et al.
Publicado: (2021)

Role of PCIF1‐mediated 5′‐cap N6‐methyladeonsine mRNA methylation in colorectal cancer and anti‐PD‐1 immunotherapy
por: Wang, Lingling, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

PTPN2 in the Immunity and Tumor Immunotherapy: A Concise Review
por: Song, Jiachun, et al.
Publicado: (2022)

Identification of Small Molecule Enhancers of Immunotherapy for Melanoma
por: Dextras, Christopher, et al.
Publicado: (2020)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
por: Liang, Shuwei, et al.
Publicado: (2023)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment
por: Li, Na, et al.
Publicado: (2020)

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
por: Baumgartner, Christina K., et al.
Publicado: (2023)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
por: Cubas, Rafael, et al.
Publicado: (2020)

Immune checkpoint PTPN2 predicts prognosis and immunotherapy response in human cancers
por: Tang, Xiaolong, et al.
Publicado: (2023)

KIAA1429/VIRMA promotes breast cancer progression by m(6)A‐dependent cytosolic HAS2 stabilization
por: Li, Na, et al.
Publicado: (2023)

Critical roles of PTPN family members regulated by non-coding RNAs in tumorigenesis and immunotherapy
por: Tang, Xiaolong, et al.
Publicado: (2022)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
por: Serratì, Simona, et al.
Publicado: (2022)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
por: Vera Aguilera, Jesus, et al.
Publicado: (2020)

Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics
por: Khan, Mohd Wajid Ali, et al.
Publicado: (2023)

Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis
por: Guo, Weinan, et al.
Publicado: (2022)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

A kinase inhibitor screen identifies small-molecule enhancers of reprogramming and iPS cell generation
por: Li, Zhonghan, et al.
Publicado: (2012)

Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
por: Ganesan, Aravindhan, et al.
Publicado: (2019)

The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
por: Zhong, Yanwen, et al.
Publicado: (2019)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

m(6)A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy
por: Wang, Lingling, et al.
Publicado: (2020)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

Concomitant deletion of Ptpn6 and Ptpn11 in T cells fails to improve anticancer responses
por: Ventura, Pedro M O, et al.
Publicado: (2022)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
por: Schlicher, Lisa, et al.
Publicado: (2023)

Targeting regulatory T cells for immunotherapy in melanoma
por: Huang, Lili, et al.
Publicado: (2021)

PTPN11 Mosaicism Causes a Spectrum of Pigmentary and Vascular Neurocutaneous Disorders and Predisposes to Melanoma
por: Polubothu, Satyamaanasa, et al.
Publicado: (2023)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

The role of mitochondria in the resistance of melanoma to PD-1 inhibitors
por: Du, Fei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ocugl5ej4dtpu1lc38fh2ll9eh